Jiangxi Institute of Biological Products (HKSE:06915) Common Stock: HK$300.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06915 Jiangxi Institute of Biological Products Inc HKSE:06915
23 GF Score
Price HK$16.72
! 3 Warning Signs
View Full Analysis

What is Jiangxi Institute of Biological Products Common Stock?

Jiangxi Institute of Biological Products HKSE:06915 +1.33% 23 Common Stock is HK$300.6 Mil as of Dec. 2025. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Jiangxi Institute of Biological Products's quarterly common stock declined from Dec. 2023 (HK$297.7 Mil) to Dec. 2024 (HK$290.6 Mil) but then increased from Dec. 2024 (HK$290.6 Mil) to Dec. 2025 (HK$300.6 Mil).

Jiangxi Institute of Biological Products's annual common stock declined from Dec. 2023 (HK$297.7 Mil) to Dec. 2024 (HK$290.6 Mil) but then increased from Dec. 2024 (HK$290.6 Mil) to Dec. 2025 (HK$300.6 Mil).

Jiangxi Institute of Biological Products Common Stock Historical Data

* Premium members only.

The historical data trend for Jiangxi Institute of Biological Products's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Institute of Biological Products Common Stock Chart

Jiangxi Institute of Biological Products Annual Data
Trend Dec23 Dec24 Dec25
Common Stock
297.66 290.56 300.64

Jiangxi Institute of Biological Products Semi-Annual Data
Dec23 Dec24 Dec25
Common Stock 297.66 290.56 300.64
HKSE:06915
23GF Score
Jiangxi Institute of Biological Products Inc HKSE:06915
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Institute of Biological Products Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of HK$300.6 Mil mean?
Jiangxi Institute of Biological Products (HKSE:06915) has a Common Stock of HK$300.6 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Jiangxi Institute of Biological Products and its competitors.
Is Jiangxi Institute of Biological Products' Common Stock too high?
Jiangxi Institute of Biological Products' current Common Stock is HK$300.6 Mil. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Common Stock compare to LLY and JNJ?
Jiangxi Institute of Biological Products' Common Stock of HK$300.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Jiangxi Institute of Biological Products and its competitors. Jiangxi Institute of Biological Products's current Common Stock is HK$300.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Common Stock of HK$300.6 Mil. The current Common Stock is HK$300.6 Mil. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Common Stock is HK$300.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jiangxi Institute of Biological Products Business Description

Address No. 198 Huoju Avenue, Jinggangshan Economic and Technological Development Zone, Jiangxi Province, Ji’an, CHN
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score

Get the complete analysis for HKSE:06915

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.72
Price